Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Anesthesiology and Intensive Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
J Diabetes Investig. 2023 Nov;14(11):1312-1317. doi: 10.1111/jdi.14068. Epub 2023 Aug 15.
AIMS/INTRODUCTION: Diabetes is a major risk factor for coronavirus disease 2019 (COVID-19) severity. We aimed to retrospectively investigate the rates of patients with no diabetes, untreated diabetes, treated diabetes, COVID-19-related diabetes and the factors associated with bleeding complications in a cohort of patients with severe COVID-19.
This was a multicenter, retrospective, observational study. Participants were COVID-19 patients enrolled in the Cross-sectional ICU Information Search System (CRISIS) from February 2020 to March 2022. Patients were classified into four groups according to diabetes status and treatment status. Hemorrhagic complications were defined as bleeding requiring transfusion of four or more red blood cell units, a drop of hemoglobin of ≥2 g in 24 h and retroperitoneal, airway or intracranial bleeding. Logistic regression analysis was carried out to examine factors associated with bleeding complications.
A total of 1,076 patients were included in the analysis. The rates of patients in the no diabetes, untreated diabetes, treated diabetes and COVID-19-related diabetes groups were 17.4, 23.0, 23.9 and 35.7%, respectively. Bleeding complications were observed in 7.5% of all patients. Glycated hemoglobin level and renal failure were significantly correlated with bleeding complications (odds ratio 1.16, 95% confidence interval 1.02-1.33 and 2.77, 95% confidence interval 1.16-6.63, respectively). Patients with diabetes, including those with COVID-19-related diabetes, accounted for approximately 83% of all cases.
In patients with severe COVID-19 with high glycated hemoglobin and renal failure, we recommend additional attention to the course of COVID-19, given the risk of bleeding complications.
目的/引言:糖尿病是 2019 年冠状病毒病(COVID-19)严重程度的主要危险因素。我们旨在回顾性调查一组严重 COVID-19 患者中无糖尿病、未治疗糖尿病、治疗糖尿病、COVID-19 相关糖尿病的患者比例以及与出血并发症相关的因素。
这是一项多中心、回顾性、观察性研究。参与者为 2020 年 2 月至 2022 年 3 月期间纳入 Cross-sectional ICU Information Search System(CRISIS)的 COVID-19 患者。根据糖尿病状况和治疗状况,患者分为四组。出血并发症定义为需要输注 4 个或更多单位红细胞、24 小时内血红蛋白下降≥2 g 和腹膜后、气道或颅内出血的出血。进行逻辑回归分析以检查与出血并发症相关的因素。
共有 1076 名患者纳入分析。无糖尿病、未治疗糖尿病、治疗糖尿病和 COVID-19 相关糖尿病组的患者比例分别为 17.4%、23.0%、23.9%和 35.7%。所有患者中有 7.5%出现出血并发症。糖化血红蛋白水平和肾功能衰竭与出血并发症显著相关(比值比 1.16,95%置信区间 1.02-1.33 和 2.77,95%置信区间 1.16-6.63)。包括 COVID-19 相关糖尿病在内的糖尿病患者约占所有病例的 83%。
在伴有高糖化血红蛋白和肾功能衰竭的严重 COVID-19 患者中,鉴于出血并发症的风险,我们建议额外关注 COVID-19 的病程。